Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | PTGIR | P43119 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1757639 | 0.89 | PTGDR2 (1.00) | PTGDR2PTGDRCYP1A2CYP3A4CYP2C8 | |
| SCHEMBL1757595 | 0.85 | PTGDR2 (0.75) | PTGDR2 | |
| SCHEMBL1757857 | 0.85 | PTGDR2 (0.86) | PTGDR2PTGDRCYP1A2CYP3A4CYP2C8 | |
| SCHEMBL1757658 | 0.85 | PTGDR2 (0.84) | PTGDR2PTGDRCYP1A2CYP3A4CYP2C8 | |
| SCHEMBL1757391 | 0.84 | PTGDR2 (0.84) | PTGDR2PTGDRCYP1A2CYP3A4CYP2C8 | |
| SCHEMBL1757541 | 0.83 | PTGDR2 (1.00) | PTGDR2PTGDRCYP1A2CYP3A4CYP2C8 | |
| SCHEMBL1757560 | 0.83 | PTGDR2 (1.00) | PTGDR2PTGDRCYP1A2CYP3A4CYP2C8 | |
| SCHEMBL1757635 | 0.82 | PTGDR2 (1.00) | PTGDR2PTGDRCYP1A2CYP3A4CYP2C8 | |
| SCHEMBL1757731 | 0.82 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1757461 | 0.82 | PTGDR2 (1.00) | PTGDR2PTGDRCYP1A2CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011055270-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH LLC (US) | 2011-05-12 | — | — | WO | claimed |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | claimed |
| WO-2011055270-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | HRH2, CRHR2, CRHR1 | PTGDR2 13/4885PTGDR 12/4885CYP1A2 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.